Ascendis Pharma (ASND1N) AI Stock Analysis

Ascendis Pharma

(BMV:ASND1N)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rapid product revenue growthRapid growth across YORVIPATH, SKYTROFA and newly launched YUVIWEL shows that Ascendis is building a multi-product commercial base. Continued patient enrollment and management’s reiterated growth outlook could support durable revenue expansion as launches mature across additional markets.

Negative Factors

Profitability remains historically inconsistentThe recent profit inflection has not yet been demonstrated across a full business cycle. Prior losses and deeply negative operating margins indicate that earnings and cash generation may remain sensitive to launch timing, investment levels and product performance as Ascendis scales.

Ascendis Pharma (ASND1N) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 16.53B
Dividend Yield: ―
Average Volume (3M): 192
Price to Earnings (P/E): 18.5
Beta (1Y): -0.01
Revenue Growth: 106.21%
EPS Growth: ―
Country: Mexico
Employees: 1,189
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ascendis Pharma Business Overview & Revenue Model

Company Description

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals...

Ascendis Pharma Earnings Call Summary

Earnings Call Date:Aug 12, 2026(Q2-2026)|% Change Since:-2.45%|Next Earnings Date:Nov 10, 2026

Earnings Call SentimentPositive

The call conveyed strong commercial momentum and clear early successes: double-digit top-line expansion with EUR 315 million in product revenue, blockbuster-level performance from YORVIPATH (EUR 252 million), a successful SKYTROFA base (>20,000 patients), and a promising early U.S. launch for YUVIWEL with rapid enrollments and reimbursement approvals. Robust clinical readouts (COACH arm-span gains) and progressing partnerships reinforce long-term upside. Offsetting these positives were elevated R&D and SG&A spending, reliance on a one-time PRV sale to bolster reported profit (non-IFRS net profit materially lower at EUR 61 million), and legal/regulatory uncertainties (U.S. IP dispute and confirmatory trial dependence). Overall, highlights outweigh the lowlights given accelerating commercial traction, a strong cash position and no debt, but investors should monitor expense trajectory and the legal/regulatory developments.

Positive Updates

Strong Top-Line Growth

Total product revenue of EUR 315 million in Q2 2026 (more than double year-over-year) and total revenue of EUR 339 million including EUR 24 million in non-product collaboration revenue (EUR 17 million milestone related to TransCon CNP).

Negative Updates

High One-Time Income Driving Reported Profit

Reported operating profit of EUR 220 million was materially supported by EUR 158 million of other operating income related to sale of a Priority Review Voucher (PRV); non-IFRS net profit was EUR 61 million, highlighting a sizable disconnect between reported and adjusted earnings.

Company Guidance

The company reiterated near‑term and long‑term guidance alongside its Q2 metrics: Q2 total product revenue was EUR 315m (total revenue EUR 339m, including EUR 24m non‑product collaboration revenue and a EUR 17m milestone), with YORVIPATH EUR 252m, SKYTROFA EUR 55m and newly launched YUVIWEL EUR 8m; Q2 R&D was EUR 76m and SG&A EUR 173m; operating profit was EUR 220m (including EUR 158m PRV sale), non‑IFRS operating profit EUR 92m (27% margin), net profit EUR 207m and non‑IFRS net profit EUR 61m, ending cash EUR 812m after EUR 56m of buybacks, no bank or convertible debt and EUR 1.4bn of equity. For the rest of 2026 management expects YORVIPATH growth “consistent with prior quarters,” relatively stable SKYTROFA U.S. revenue, continuing strong early demand for YUVIWEL (U.S. regulatory decision expected Q4 2026), plans to file at least one IND/CTA per year for new NCEs, anticipates significant operating leverage as revenue scales and reiterates generating greater than EUR 500m of operating cash flow this year while targeting ~EUR 5bn revenue in 2030 and >EUR 10bn over the following decades.

Ascendis Pharma Risk Analysis

Ascendis Pharma disclosed 93 risk factors in its most recent earnings report. Ascendis Pharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We may use artificial intelligence ("AI") in our business, and challenges with properly managing its use, as well as uncertainty regarding the legal landscape surrounding the use of AI could adversely affect our business.Q4, 2025

2.If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in which we participate, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.Q4, 2025

3.If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs that we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.Q4, 2025

Ascendis Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ASND1N against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	69Neutral	$1.95B	-110.30	-426.33%	―	36.33%	54.68%
BMRN	61Neutral	$11.33B	153.97	1.18%	―	13.69%	-89.03%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	47Neutral	$2.69B	-23.28	-26.01%	―	―	-4.40%
RARE	43Neutral	$1.59B	-2.76	392.35%	―	17.50%	-5.66%

* Healthcare Sector Average

Performance Comparison

MX:ASND1N and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ASND1N	Ascendis Pharma A/S	4165.55	618.44	17.44%
BMRN	Biomarin Pharmaceutical Inc.	58.51	5.66	10.71%
RARE	Ultragenyx Pharmaceutical, Inc.	16.10	-17.37	-51.90%
XERS	Xeris Pharmaceuticals	10.71	0.81	8.18%
MBX	MBX Biosciences, Inc.	55.87	35.26	171.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ascendis Pharma AI Stock Analysis